ORPHA:876
Yolk sac tumor
Also known as: Endodermal sinus tumor
Publications
7,652
Trials
21
Interventional, condition-specific
Researchers
1,132
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare germ cell tumor characterized by multiple patterns reflecting endodermal extraembryonal differentiation (secondary yolk sac and allantois) or endodermal somatic tissues (intestine, liver, and mesenchyme). The tumors most commonly occur in the second or third decade of life. They are typically located in the gonads, occasionally also in other regions. Patients present with a pelvic mass and/or abdominal pain (females) or an often painless, unilateral testicular mass (males). Elevated serum alpha fetoprotein is a common laboratory finding.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0005744
- UMLS:C0014145
- NCIT:C3011
Additional Mondo synonyms (9)
endodermal sinus neoplasm · endodermal sinus tumor · hepatoid yolk sac tumor · yolk SAC tumor, malignant · yolk Sac neoplasm · yolk Sac tumor · yolk Sac tumor site unspecified · yolk Sac tumour site unspecified · yolk sac tumor
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
7,652 matched papers (3,729 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
21 matched on ClinicalTrials.gov (7 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
7,652
7,652 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
7,652 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
3,729 in the last 10 years · low confidence
Phrase hits: 7,652 · MeSH hits: 0
Who's working on it?
1,132
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Ulbright TM13 papers · 2026
Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA.
Papers in Europe PMC - 02Acosta AM11 papers · 2026
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
Papers in Europe PMC - 03Idrees MT8 papers · 2026
Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN.
Papers in Europe PMC - 04Ricci C8 papers · 2026
Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
Papers in Europe PMC - 05Yang J7 papers · 2026
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Obstetric & Gynecologic Diseases, Beijing, China. Electronic address: yangjiaxin@pumch.cn.
Papers in Europe PMC - 06Fiorentino M6 papers · 2026
Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy. Electronic address: michelangelo.fiorentino@unibo.it.
Papers in Europe PMC - 07Ambrosi F5 papers · 2026
Pathology Unit, Maggiore Hospital-AUSL Bologna, Bologna, Italy; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
Papers in Europe PMC - 08Zhang X5 papers · 2025
Department of Pathology, Jining No. 1 People's Hospital, Jining, Shandong, China.
Papers in Europe PMC - 09Zhang Y5 papers · 2026
Department of Urology, Anhui Provincial Children's Hospital, Children's Hospital of Fudan University (Affiliated Anhui Branch), No. 39 Wangjing East Road, Hefei, 230000, Anhui Province, People's Republic of China.
Papers in Europe PMC - 10Cao D4 papers · 2026
National Clinical Research Center for Obstetric and Gynecologic Diseases, Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, People's Republic of China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
21
interventional trials for this specific condition
21 interventional trials matched this specific condition name; 7 currently recruiting in our sample.
Data as of 27 July 2026
21 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 94.7th percentile).
low confidence · 94.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
21 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07224568·NOT YET RECRUITING·Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
Conditions: Solid Tumor (Excluding CNS) · Hepatocellular Carcinoma · Liver Cell Carcinoma · Liposarcoma·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT06198296·RECRUITING·Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Conditions: Hepatoblastoma · Hepatocellular Carcinoma · Wilms Tumor · Malignant Rhabdoid Tumor·Matched via name phrase
- NCT04684368·RECRUITING·A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor · Choriocarcinoma · Embryonal Carcinoma · Immature Teratoma·Matched via name phrase
- NCT03067181·RECRUITING·Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Conditions: Childhood Extracranial Germ Cell Tumor · Extragonadal Embryonal Carcinoma · Germ Cell Tumor · Malignant Germ Cell Tumor·Matched via name phrase
- NCT04715191·RECRUITING·Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Conditions: Liver Cancer · Rhabdomyosarcoma · Malignant Rhabdoid Tumor · Liposarcoma·Matched via name phrase
- NCT07148050·RECRUITING·Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Conditions: Solid Tumor (Excluding CNS) · Liver Cell Carcinoma · Malignant Rhabdoid Tumor · Yolk Sac Tumor·Matched via name phrase
Observational and natural-history studies
4 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05564026·RECRUITING·Molecular Epidemiology of Pediatric Germ Cell Tumors
Conditions: Germ Cell Tumor · Germinoma · Teratoma · Embryonal Carcinoma·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Yolk sac tumor" OR "Endodermal sinus tumor" OR "endodermal sinus neoplasm" OR "hepatoid yolk sac tumor" OR "yolk SAC tumor, malignant" OR "yolk Sac neoplasm" OR "yolk Sac tumor site unspecified" OR "yolk Sac tumour site unspecified"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Yolk sac tumor" OR "Endodermal sinus tumor" OR "endodermal sinus neoplasm" OR "hepatoid yolk sac tumor" OR "yolk SAC tumor, malignant" OR "yolk Sac neoplasm" OR "yolk Sac tumor site unspecified" OR "yolk Sac tumour site unspecified"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 21 interventional · 4 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (7652) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T15:43:32.932Z
